Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
28 Octobre 2021 - 5:11PM
InvestorsHub NewsWire
San Francisco, CA -- October 28, 2021 -- InvestorsHub
NewsWire -- Oncology Pharma
Inc. (OTC: ONPH) Pursuant to previous communications,
Oncology Pharma, Inc. (the "Company") is making progress towards
pursuing its primary goal of the Co-Development plan to bring
new pharmaceutical drug formulations to market with a focused
approach that aims to reduce overall costs and minimize time and
duration to commercialization.
The Company has developed the framework for early feasibility and
initial non-clinical studies; and is in the process of creating
data that focuses on using a dactinomycin nanoemulsion drug
product, intended for the treatment of pediatric cancer.
Dactinomycin has been shown to be effective in destroying cancer
cells. Utilizing the Nanoemulsion for the targeted delivery
system is expecting to allow a safe dose of the drug to be
delivered over time, so it may be safely administered.
The Company is further planning on a November meeting with its
Board of Directors, Scientific Advisory Board, co-development
partners and other advisors to discuss and present the ongoing data
development, status of license agreements, commercialization and
any further developments with its partner companies.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the "Company") is currently
engaging in research and development of therapeutics for oncology
and prides itself for having a world-class Advisory Board that
keeps the Company in the forefront of developing technologies in
cancer research, biotechnology, and healthcare.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Oncology Pharma (CE) (USOTC:ONPH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Oncology Pharma Inc (CE) (OTCMarkets): 0 recent articles
Plus d'articles sur Oncology Pharma Inc (PK)